TR201903509T4 - Diyabet ile ilişkili kronik komplikasyonlarda kullanıma yönelik socs1-türevli peptit. - Google Patents

Diyabet ile ilişkili kronik komplikasyonlarda kullanıma yönelik socs1-türevli peptit. Download PDF

Info

Publication number
TR201903509T4
TR201903509T4 TR2019/03509T TR201903509T TR201903509T4 TR 201903509 T4 TR201903509 T4 TR 201903509T4 TR 2019/03509 T TR2019/03509 T TR 2019/03509T TR 201903509 T TR201903509 T TR 201903509T TR 201903509 T4 TR201903509 T4 TR 201903509T4
Authority
TR
Turkey
Prior art keywords
socs1
derived peptide
diabetes
complications associated
chronic complications
Prior art date
Application number
TR2019/03509T
Other languages
English (en)
Inventor
Egido De Los Ríos Jesús
GÓMEZ GUERRERO Carmen
SIMÓ CANONGE Rafael
HERNÁNDEZ PASCUAL Cristina
Original Assignee
Fundacio Hospital Univ Vall Dhebron Institut De Recerca
Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Hospital Univ Vall Dhebron Institut De Recerca, Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz, Univ Madrid Autonoma filed Critical Fundacio Hospital Univ Vall Dhebron Institut De Recerca
Publication of TR201903509T4 publication Critical patent/TR201903509T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, özellikle oküler, renal, sinirsel ve vasküler komplikasyonlar olmak üzere kronik diyabet komplikasyonlarında kullanıma yönelik bir SOCS1-türevli peptit, bunu içeren bileşimler ve bunu kodlayan izole edilmiş polinükleotidler ile ilgilidir. Mevcut buluş aynı zamanda özellikle diyabetik retinopatinin erken aşamaları ve nörodejenerasyonun önemli bir rol oynadığı diğer retina hastalıkları olmak üzere nörodejeneratif retina hastalıklarının tedavisinde ve/veya önlenmesinde topikal kullanıma yönelik SOCS1-türevli peptit ile ilgilidir.
TR2019/03509T 2014-05-28 2015-05-27 Diyabet ile ilişkili kronik komplikasyonlarda kullanıma yönelik socs1-türevli peptit. TR201903509T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430796A ES2552587B1 (es) 2014-05-28 2014-05-28 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Publications (1)

Publication Number Publication Date
TR201903509T4 true TR201903509T4 (tr) 2019-04-22

Family

ID=53546661

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03509T TR201903509T4 (tr) 2014-05-28 2015-05-27 Diyabet ile ilişkili kronik komplikasyonlarda kullanıma yönelik socs1-türevli peptit.

Country Status (13)

Country Link
US (2) US10532082B2 (tr)
EP (1) EP3178485B1 (tr)
JP (1) JP6681387B2 (tr)
CN (1) CN107074922A (tr)
BR (1) BR112016027936A2 (tr)
CA (1) CA2950348A1 (tr)
ES (2) ES2552587B1 (tr)
HU (1) HUE041836T2 (tr)
MX (1) MX369378B (tr)
PL (1) PL3178485T3 (tr)
PT (1) PT3178485T (tr)
TR (1) TR201903509T4 (tr)
WO (1) WO2015181427A1 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
CN105315377A (zh) * 2015-12-07 2016-02-10 华东理工大学 带有穿膜肽的tcs融合蛋白、质粒及制备方法与应用
US20200206299A1 (en) * 2016-02-23 2020-07-02 Takeda Pharmaceutical Company Limited Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain
CN106349347B (zh) * 2016-10-25 2019-09-13 南通大学 一种小分子多肽、及其编码基因和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175971A1 (en) * 2001-12-28 2003-09-18 Geoffrey Lindeman Differentiation and/or proliferation modulating agents and uses therefor
JP2007526000A (ja) * 2004-03-04 2007-09-13 バンダービルト ユニバーシティ サイトカイン誘導性シグナル伝達を阻害する細胞透過性ｓｏｃｓポリペプチド
WO2006112869A2 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
EP1849474B1 (en) 2005-02-15 2016-09-07 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US20090253618A1 (en) 2005-07-20 2009-10-08 Hiroshi Kanno Neuronal differentiation-inducing peptide and use thereof
WO2010151495A2 (en) 2009-06-26 2010-12-29 University Of Florida Research Foundation Inc. Materials and methods for treating and preventing viral infections
US20110229525A1 (en) * 2010-03-12 2011-09-22 Vanderbilt University Modulation of cytokine signaling
WO2013020372A1 (zh) * 2011-08-09 2013-02-14 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CN103173446A (zh) * 2011-12-26 2013-06-26 吕成伟 一种靶向干扰socs1基因的重组腺相关病毒载体的构建方法与应用
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Also Published As

Publication number Publication date
MX369378B (es) 2019-11-07
ES2715412T3 (es) 2019-06-04
US10532082B2 (en) 2020-01-14
US20200138903A1 (en) 2020-05-07
MX2016015514A (es) 2017-05-04
EP3178485B1 (en) 2018-12-12
HUE041836T2 (hu) 2019-05-28
JP6681387B2 (ja) 2020-04-15
PL3178485T3 (pl) 2019-07-31
EP3178485A1 (en) 2017-06-14
CN107074922A (zh) 2017-08-18
WO2015181427A1 (es) 2015-12-03
JP2017524727A (ja) 2017-08-31
ES2552587B1 (es) 2017-01-18
US20170209536A1 (en) 2017-07-27
ES2552587A2 (es) 2015-11-30
PT3178485T (pt) 2019-03-22
ES2552587R1 (es) 2016-02-10
BR112016027936A2 (pt) 2017-10-24
CA2950348A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
AU2018260800A1 (en) Hepcidin analogues and uses therof
PL2968471T3 (pl) Peptydy do stosowania w miejscowym leczeniu chorób neurodegeneracyjnych siatkówki, w szczególności we wczesnych stadiach retinopatii cukrzycowej i innych chorób siatkówki, w których neurodegeneracja odgrywa znaczącą rolę
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
NZ733962A (en) Cysteine protease
WO2013166449A3 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
AU2014209387A8 (en) Toxic aldehyde related diseases and treatment
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2021008663A (es) Anticuerpos mejorados contra il-6.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2015015249A (es) Peptidos terapeuticos.
TR201903509T4 (tr) Diyabet ile ilişkili kronik komplikasyonlarda kullanıma yönelik socs1-türevli peptit.
MA40709A1 (fr) Dérivé du glucagon à stabilité améliorée
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2016011881A (es) Medicamento de peptido en polvo seco.
WO2015022530A3 (en) Materials and methods relating to pancreatic cancer
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
BR112018072127A2 (pt) inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
PH12016502006B1 (en) A prodrug of 1,1`-(1,6-dioxo-1,6-hexanediyl)bis-d-proline
WO2014145289A3 (en) Compositions derived from sweet potato greens and methods of preparation and use
PH12017501979A1 (en) Pharmaceutical compound
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция